Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics Inc. (Nasdaq: CMPX) advances novel antibody therapies targeting cancer's complex biology through its clinical-stage pipeline. This dedicated news center provides investors and researchers with essential updates on oncology developments, trial milestones, and scientific breakthroughs.
Access timely reports on bispecific antibody programs, including Tovecimig (CTX-009) for biliary tract cancers and CTX-471's CD137 agonist mechanism. Track regulatory progress across multiple indications and discover partnership announcements leveraging Compass' StitchMabs platform technology.
Our curated news collection serves as your primary source for:
- Phase 1-3 clinical trial updates
- FDA submissions and international regulatory milestones
- Peer-reviewed research publications
- Strategic collaborations in immuno-oncology
Bookmark this page for real-time insights into Compass' work on angiogenesis modulation and tumor microenvironment targeting. Monitor biomarker-driven developments that could shape next-generation cancer treatments.
BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the Stifel 2023 Virtual Targeted Oncology Days, scheduled for April 25 – 26, 2023. The company will engage in a fireside chat on April 26 at 11 AM ET, which can be accessed via a webcast. The corporate presentation will be archived for 90 days on their Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics aimed at treating various human diseases. Central to their research is the relationship between angiogenesis, the immune system, and tumor growth. Their innovative pipeline targets critical biological pathways to enhance anti-tumor responses. For further details, visit www.compasstherapeutics.com.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the Cantor Fitzgerald Future of Oncology Symposium scheduled for April 3-5, 2023. The company will present on April 4 at 8:15 AM ET. Compass Therapeutics is developing proprietary antibody-based therapeutics targeting various human diseases, emphasizing the interplay between angiogenesis, the immune system, and tumor growth. Their innovative pipeline aims to address critical biological pathways for effective anti-tumor responses, advancing both standalone therapies and combination strategies. Founded in 2014, the company is headquartered in Boston, Massachusetts.
Compass Therapeutics (CMPX) announced several advancements in its clinical pipeline, including the initiation of U.S. Phase 2/3 trials for CTX-009 targeting advanced biliary tract cancers (BTC) and colorectal cancer (CRC). The company presented promising Phase 2 results at the 2023 ASCO GI Cancers Symposium, reporting a 37.5% overall response rate (ORR) in BTC patients. Financially, Compass ended 2022 with $187 million in cash, ensuring a runway until 2026. The net loss for the year was $39.2 million, a reduction from $82.2 million in 2021 due to decreased non-recurrent R&D expenses. Initial results from current trials are expected in 2023 and 2024.
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in the SVB Securities Global Biopharma Conference, scheduled for February 13-16, 2023. A significant event will be the fireside chat on February 15 at 11:20 AM ET, accessible via a live webcast. Investors can view the archived presentation for 90 days on the Company’s Events page. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting oncology and aims to advance its products through clinical development, addressing critical biological pathways for effective anti-tumor responses.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced promising data from a Phase 2 study of CTX-009 combined with paclitaxel for biliary tract cancers (BTC). The study revealed a 37.5% overall response rate (ORR) across all 24 patients, with a notable 63.6% ORR in the second-line subgroup. Median progression-free survival (PFS) was 9.4 months and overall survival (OS) was 12.5 months. Safety profiles were consistent with prior studies, as 95.8% of patients experienced grade 3 or higher treatment-emergent adverse events. A randomized Phase 2/3 trial of CTX-009 in the U.S. has been initiated, potentially supporting a biologics license application in 2024.
Compass Therapeutics, Inc. (Nasdaq: CMPX) has announced the dosing of the first patient in a Phase 2 clinical study of CTX-009 for metastatic colorectal cancer. This study targets patients who have undergone at least two previous therapies and will evaluate safety and clinical response. The drug is designed to block critical cancer pathways, with prior Phase 1 studies showing confirmed responses. Preliminary results are expected mid-2023, marking a significant development in treatment options for patients facing limited therapies.
Compass Therapeutics, Inc. (CMPX) announced updated Phase 2 study results for CTX-009 combined with paclitaxel in biliary tract cancer (BTC) to be presented at the 2023 ASCO GI Symposium in San Francisco, January 19-21. The event will also showcase ongoing studies including a Phase 2/3 trial for BTC and a Phase 2 trial for metastatic colorectal cancer (CRC).
The presentations aim to highlight the therapeutic potential of CTX-009, which targets DLL4 and VEGF A, and its impact on patient outcomes.
Compass Therapeutics (Nasdaq: CMPX) announced the first patient dosed in a Phase 1b study of CTX-471 combined with KEYTRUDA® for treating advanced solid tumors, including lung and head & neck cancers.
The study aims to evaluate CTX-471's ability to restore responses after checkpoint inhibitor therapy. Previous monotherapy results showed signs of activity.
CTX-471 is a CD137 agonist that activates key immune cells. Four partial responses were observed in earlier trials as of September 30, 2022.
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on cancer treatment, will participate in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York City. The company's presentation is scheduled for December 1, 2022, at 8:50 AM ET. A webcast link will be available on their website, and the corporate presentation will be archived for 90 days. Compass Therapeutics is dedicated to developing antibody-based therapies targeting key biological pathways to enhance anti-tumor responses.
Compass Therapeutics (CMPX) announced financial results for Q3 2022, reporting a net loss of $12 million, or $0.12 per share, compared to $6 million, or $0.10 per share, in Q3 2021. Cash and marketable securities were $120.6 million, down from $144.5 million at the end of 2021. The company raised approximately $80 million through a PIPE financing to extend its cash runway into 2026. Key clinical trials for CTX-009 and CTX-471 are underway, with patient enrollment expected to start in Q4 2022. R&D expenses surged by 210% year-over-year, reflecting increased development activities.
